These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 23694816)

  • 1. Assessment of the efficacy of 8 weeks of primaquine for the prevention of relapse in vivax malaria patients using SSCP-PCR and sequencing in South and South-East Iran, 2008-2011.
    Miahipour A; Keshavarz H; Heidari A; Raeisi A; Rezaeian M; Rezaei S
    Trans R Soc Trop Med Hyg; 2013 Jul; 107(7):420-6. PubMed ID: 23694816
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized trial of 3-dose regimens of tafenoquine (WR238605) versus low-dose primaquine for preventing Plasmodium vivax malaria relapse.
    Walsh DS; Wilairatana P; Tang DB; Heppner DG; Brewer TG; Krudsood S; Silachamroon U; Phumratanaprapin W; Siriyanonda D; Looareesuwan S
    Clin Infect Dis; 2004 Oct; 39(8):1095-103. PubMed ID: 15486831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular assessment of dhfr/dhps mutations among Plasmodium vivax clinical isolates after introduction of sulfadoxine/pyrimethamine in combination with artesunate in Iran.
    Afsharpad M; Zakeri S; Pirahmadi S; Djadid ND
    Infect Genet Evol; 2012 Jan; 12(1):38-44. PubMed ID: 22020253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic efficacy of chloroquine and chloroquine plus primaquine for the treatment of Plasmodium vivax in Ethiopia.
    Yeshiwondim AK; Tekle AH; Dengela DO; Yohannes AM; Teklehaimanot A
    Acta Trop; 2010 Feb; 113(2):105-13. PubMed ID: 19835832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo sensitivity monitoring of chloroquine for the treatment of uncomplicated vivax malaria in four bordered provinces of Thailand during 2009-2010.
    Congpuon K; Satimai W; Sujariyakul A; Intanakom S; Harnpitakpong W; Pranuth Y; Cholpol S; Bualombai P
    J Vector Borne Dis; 2011 Dec; 48(4):190-6. PubMed ID: 22297279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High rate of detection of mixed infections of Plasmodium vivax and Plasmodium falciparum in South-East of Iran, using nested PCR.
    Ebrahimzadeh A; Fouladi B; Fazaeli A
    Parasitol Int; 2007 Mar; 56(1):61-4. PubMed ID: 17257891
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study.
    Llanos-Cuentas A; Lacerda MV; Rueangweerayut R; Krudsood S; Gupta SK; Kochar SK; Arthur P; Chuenchom N; Möhrle JJ; Duparc S; Ugwuegbulam C; Kleim JP; Carter N; Green JA; Kellam L
    Lancet; 2014 Mar; 383(9922):1049-58. PubMed ID: 24360369
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radical curative efficacy of five-day regimen of primaquine for treatment of Plasmodium vivax malaria in India.
    Yadav RS; Ghosh SK
    J Parasitol; 2002 Oct; 88(5):1042-4. PubMed ID: 12435158
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of three chloroquine-primaquine regimens for treatment of Plasmodium vivax malaria in Colombia.
    Alvarez G; Piñeros JG; Tobón A; Ríos A; Maestre A; Blair S; Carmona-Fonseca J
    Am J Trop Med Hyg; 2006 Oct; 75(4):605-9. PubMed ID: 17038680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Case report: An unusual late relapse of Plasmodium vivax malaria.
    Durante Mangoni E; Severini C; Menegon M; Romi R; Ruggiero G; Majori G
    Am J Trop Med Hyg; 2003 Feb; 68(2):159-60. PubMed ID: 12641405
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of a 14-day primaquine regimen in preventing relapses in patients with Plasmodium vivax malaria in Mumbai, India.
    Rajgor DD; Gogtay NJ; Kadam VS; Kamtekar KD; Dalvi SS; Chogle AR; Aigal U; Bichile LS; Kain KC; Kshirsagar NA
    Trans R Soc Trop Med Hyg; 2003; 97(4):438-40. PubMed ID: 15259476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regional differences in the response of Plasmodium vivax malaria to primaquine as anti-relapse therapy.
    Goller JL; Jolley D; Ringwald P; Biggs BA
    Am J Trop Med Hyg; 2007 Feb; 76(2):203-7. PubMed ID: 17297026
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relapse of imported vivax malaria despite standard-dose primaquine therapy: an investigation with molecular genotyping analyses.
    Chiang TY; Lin WC; Kuo MC; Ji DD; Fang CT
    Clin Microbiol Infect; 2012 Jul; 18(7):E232-4. PubMed ID: 22448875
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention of Plasmodium vivax malaria recurrence: efficacy of the standard total dose of primaquine administered over 3 days.
    Carmona-Fonseca J; Maestre A
    Acta Trop; 2009 Nov; 112(2):188-92. PubMed ID: 19653988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic assessment of chloroquine-primaquine combined regimen in adult cohort of Plasmodium vivax malaria from a tertiary care hospital in southwestern India.
    Rishikesh K; Kamath A; Hande MH; Vidyasagar S; Acharya RV; Acharya V; Belle J; Shastry AB; Saravu K
    Malar J; 2015 Aug; 14():310. PubMed ID: 26259839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population structure analysis of Plasmodium vivax in areas of iran with different malaria endemicity.
    Zakeri S; Mehrizi AA; Mamaghani S; Noorizadeh S; Snounou G; Djadid ND
    Am J Trop Med Hyg; 2006 Mar; 74(3):394-400. PubMed ID: 16525096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Studies on Plasmodium vivax relapse pattern in Kheda district, Gujarat.
    Srivastava HC; Sharma SK; Bhatt RM; Sharma VP
    Indian J Malariol; 1996 Dec; 33(4):173-9. PubMed ID: 9125831
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic efficacy of artesunate in Plasmodium vivax malaria in Thailand.
    Hamedi Y; Safa O; Zare S; Tan-ariya P; Kojima S; Looareesuwan S
    Southeast Asian J Trop Med Public Health; 2004 Sep; 35(3):570-4. PubMed ID: 15689068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular characterization of Plasmodium vivax clinical isolates in Pakistan and Iran using pvmsp-1, pvmsp-3alpha and pvcsp genes as molecular markers.
    Zakeri S; Raeisi A; Afsharpad M; Kakar Q; Ghasemi F; Atta H; Zamani G; Memon MS; Salehi M; Djadid ND
    Parasitol Int; 2010 Mar; 59(1):15-21. PubMed ID: 19545647
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relapses contribute significantly to the risk of Plasmodium vivax infection and disease in Papua New Guinean children 1-5 years of age.
    Betuela I; Rosanas-Urgell A; Kiniboro B; Stanisic DI; Samol L; de Lazzari E; Del Portillo HA; Siba P; Alonso PL; Bassat Q; Mueller I
    J Infect Dis; 2012 Dec; 206(11):1771-80. PubMed ID: 22966124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.